Prime Medicine, Inc. (PRME) announced the FDA has cleared the company's Investigational New Drug application for PM359 for the treatment of chronic granulomatous disease, enabling the company to initiate global Phase 1/2 clinical trial in the United States.
While reporting financial results for the first quarter on Monday, ON Semiconductor Corp. (ON) provided earnings and revenue guidance for the second quarter of fiscal 2024.
IoT solutions and services company, KORE Group Holdings, Inc. (KORE), Monday announced that President and Chief Executive Officer Romil Bahl will step down from the position, and will be replaced by Ronald Totton on an interim basis, effective May 3.
Abbott Laboratories (ABT) Monday announced that the U.S. Food and Drug Administration has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System for patients suffering from chronic limb-threatening ischemia below-the-knee or CLTI-BTK.